New York-based Formation Bio, an AI-native pharma company focused on accelerating drug development, revealed that its ...

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi will explore additional indications for gusacitinib in a Phase I study.

PARIS and NEW YORK and SAN FRANCISCO, Nov. 12, 2024 /PRNewswire/ -- Today, Formation Bio, together with OpenAI and Sanofi, introduced Muse, an advanced AI-powered tool developed to accelerate and ...

“At Sanofi, we’re all in on AI,” Sanofi CEO Paul Hudson said in a press release. “And we are proud to partner with and invest in Formation Bio, whose AI-driven drug development vision and ...

There’s a new Muse in town. Sanofi, Formation Bio and OpenAI have joined forces to build an AI-powered tool designed to improve drug development by speeding up clinical trial recruitment.

Last month, Sanofi announced that it is collaborating with OpenAI and Formation Bio to boost its drug development projects through the use of artificial intelligence. The company, which did not ...

Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi.

Today, Formation Bio, together with OpenAI and Sanofi, introduced Muse, an advanced AI-powered tool developed to accelerate and improve drug development by optimizing patient recruitment for ...

(Reuters) - AI-based drug developer Formation Bio said on Wednesday that it has raised $372 million in a late-stage funding round, with a significant participation from French drugmaker Sanofi.